See analyst estimates and all valuation multiples for Biopharmaceuticals
| Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| $815B | 17.3x | 47.2x | |
| $418B | 7.4x | 16.9x | |
| $403B | 4.5x | 12.8x | |
| $401B | 9.6x | 19.6x | |
| $293B | 4.3x | 11.2x | |
| $251B | 4.5x | 13.5x | |
| $250B | 3.9x | 9.3x | |
| $232B | 4.6x | 11.1x | |
| $211B | 6.3x | 10.6x | |
| $206B | 3.2x | 8.5x | |
| $155B | 5.4x | 13.6x | |
| $154B | 3.2x | 19.6x | |
| $146B | 3.1x | 10.8x | |
| $120B | 10.8x | 75.8x | |
| $90.8B | 2.3x | 6.5x | |
| $77.0B | 9.9x | 20.2x | |
| $76.6B | 8.3x | 19.4x | |
| $72.7B | 2.4x | 8.9x | |
| $69.7B | 3.1x | 11.0x | |
| $55.8B | 1.2x | 5.3x | |
| $49.8B | 6.7x | 23.1x | |
| $43.3B | 7.2x | 25.2x | |
| $39.1B | 10.4x | 42.4x | |
| $38.0B | 3.2x | 17.2x | |
| $34.8B | 2.1x | 7.1x | |
| $27.7B | 11.0x | 36.7x | |
| $27.4B | 1.9x | 5.9x | |
| $24.8B | 2.6x | 7.5x | |
| $23.8B | 1.5x | 7.2x | |
| $23.1B | 2.4x | 6.9x | |
| $22.0B | 1.8x | 8.9x | |
| $20.3B | 7.2x | 7.8x | |
| $19.9B | 1.9x | 9.5x | |
| $14.7B | 2.0x | 8.0x | |
| $14.4B | 222.2x | 822.0x | |
| $13.2B | 5.3x | 14.4x | |
| $12.8B | 4.0x | 15.7x | |
| $12.7B | 17.7x | -143.5x | |
| $12.0B | 9.1x | 28.1x | |
| $12.0B | 1.9x | 6.1x | |
| $11.9B | 7.1x | 20.1x | |
| $11.7B | 2.1x | 15.9x | |
| $11.5B | 4.6x | 12.8x | |
| $11.4B | 4.8x | 17.2x | |
| $11.2B | 3.6x | 11.0x | |
| $11.2B | 1.9x | 13.1x | |
| $11.1B | 14.7x | 22.9x | |
| $11.0B | 3.0x | 10.9x | |
| $10.6B | 7.6x | 29.1x | |
| $10.0B | 3.9x | 17.1x | |
| $9.9B | 3.8x | 13.1x | |
| $9.5B | 3.2x | 8.1x | |
| $8.9B | 3.0x | 7.3x | |
| $8.7B | 2.4x | 6.5x | |
| $8.2B | 1.4x | 11.9x | |
| $8.0B | 6.7x | -176.6x | |
| $8.0B | 7.7x | 12.3x | |
| $8.0B | 21.9x | -377.3x | |
| $7.7B | 4.8x | 16.6x | |
| $7.6B | 2.1x | 9.9x | |
| $7.5B | 1.5x | 11.8x | |
| $7.3B | 1.8x | 6.9x | |
| $7.3B | 2.4x | 8.9x | |
| $7.1B | 16.0x | 21.4x | |
| $7.0B | n/a | n/a | |
| $6.9B | 9.4x | 36.4x | |
| $6.7B | n/a | n/a | |
| $6.5B | 1.7x | 9.5x | |
| $6.4B | 0.2x | 2.9x | |
| $6.3B | 4.3x | 71.1x | |
| $6.0B | 3.5x | 17.5x | |
| $6.0B | 4.0x | 20.3x | |
| $5.9B | 1.4x | 5.7x | |
| $5.8B | 23.2x | -184.3x | |
| $5.7B | 17.8x | 164.8x | |
| $5.7B | 4.6x | 13.7x | |
| $5.5B | 1.7x | 7.0x | |
| $5.4B | 2.2x | 8.3x | |
| $5.3B | 10.2x | 34.6x | |
| $5.1B | 3.3x | 11.9x | |
| $5.1B | 2.2x | 6.0x | |
| $5.0B | 1.8x | 7.9x | |
| $4.8B | 2.4x | 6.7x | |
| $4.8B | 5.7x | 13.6x | |
| $4.8B | 9.9x | 33.0x | |
| $4.7B | 11.7x | 32.9x | |
| $4.7B | 1.4x | 6.0x | |
| $4.7B | 2.3x | 8.6x | |
| $4.6B | 10.8x | 36.2x | |
| $4.6B | 6.6x | 22.7x | |
| $4.3B | 5.2x | n/a | |
| $4.2B | 2.7x | 15.6x | |
| $3.9B | 5.4x | 14.0x | |
| $3.8B | 8.8x | 22.0x | |
| $3.5B | 2.7x | 9.2x | |
| $3.5B | 902.1x | -14.2x | |
| $3.3B | 12.1x | -27.5x | |
| $3.2B | 1.6x | 10.9x | |
| $3.1B | 7.6x | 24.3x | |
| $3.1B | 5.1x | 22.8x | |
| $3.1B | 2.5x | 9.5x | |
| $3.1B | n/a | n/a | |
| $3.1B | 6.4x | 22.7x | |
| $3.1B | 5.1x | 18.0x | |
| $3.0B | 8.4x | 25.6x | |
| $3.0B | 3.8x | 13.4x | |
| $2.9B | 2.0x | 10.0x | |
| $2.8B | n/a | n/a | |
| $2.8B | 6.5x | 14.7x | |
| $2.7B | n/a | n/a | |
| $2.7B | n/a | n/a | |
| $2.6B | n/a | n/a | |
| $2.6B | 2.5x | 11.8x | |
| $2.5B | 25.5x | -281.7x | |
| $2.5B | 4.3x | 11.3x | |
| $2.3B | 3.2x | 17.5x | |
| $2.1B | 8.5x | -14.5x | |
| $2.0B | 2.7x | 17.3x | |
| $2.0B | 2.0x | 10.2x | |
| $2.0B | 7.5x | 15.2x | |
| $2.0B | 47.5x | -294.6x | |
| $2.0B | 8.0x | -10.5x | |
| $2.0B | n/a | n/a | |
| $2.0B | 4.9x | 14.0x | |
| $1.9B | 14.8x | 35.4x | |
| $1.9B | n/a | n/a | |
| $1.9B | 1.5x | 3.9x | |
| $1.9B | 2.5x | 6.3x | |
| $1.9B | n/a | n/a | |
| $1.9B | 2.7x | -41.4x | |
| $1.7B | 720.7x | n/a | |
| $1.7B | 2.8x | 11.1x | |
| $1.7B | n/a | n/a | |
| $1.7B | 0.7x | 3.7x | |
| $1.7B | 2.6x | 4.2x | |
| $1.7B | 14.6x | -23.1x | |
| $1.7B | 8.8x | -5011.7x | |
| $1.6B | 8.0x | -14.2x | |
| $1.6B | 1.7x | 7.6x | |
| $1.6B | 51.8x | -8.5x | |
| $1.5B | 3.7x | 20.5x | |
| $1.5B | n/a | n/a | |
| $1.5B | 11.2x | 26.5x | |
| $1.5B | 2.3x | 9.6x | |
| $1.4B | 25.1x | -9.2x | |
| $1.4B | 7.0x | -9.7x | |
| $1.4B | n/a | n/a | |
| $1.4B | 0.7x | 6.5x | |
| $1.4B | n/a | -9.6x | |
| $1.4B | 3.6x | 15.8x | |
| $1.4B | 13.6x | 156.3x | |
| $1.4B | 2.9x | 20.5x | |
| $1.3B | 3.6x | 13.6x | |
| $1.3B | 3.7x | 6.4x | |
| $1.2B | 1.8x | -10.2x | |
| $1.2B | 2.8x | -41.6x | |
| $1.2B | 43.6x | -37.5x | |
| $1.2B | 10.7x | -26.6x | |
| $1.2B | n/a | -3.8x | |
| $1.2B | 1.0x | 4.6x | |
| $1.2B | 4.2x | 25.2x | |
| $1.2B | 755.3x | n/a | |
| $1.2B | n/a | n/a | |
| $1.2B | 2.3x | 8.8x | |
| $1.2B | 27.4x | n/a | |
| $1.2B | 5.7x | 29.7x | |
| $1.1B | 7.9x | -15.9x | |
| $1.1B | 399.1x | -5.9x | |
| $1.1B | 3.3x | -213.9x | |
| $1.1B | 3.9x | 6.3x | |
| $1.1B | n/a | n/a | |
| $1.0B | 85.6x | n/a | |
| $1.0B | 739.2x | -5.1x | |
| $1.0B | n/a | n/a | |
| $993M | 18.2x | -3.1x | |
| $930M | 0.8x | 8.7x | |
| $912M | 490.8x | -10.7x | |
| $886M | n/a | n/a | |
| $883M | 7.3x | 9.7x | |
| $875M | 3.6x | 16.5x | |
| $871M | n/a | n/a | |
| $826M | 4.1x | 14.3x | |
| $816M | 2.4x | 9.3x | |
| $784M | 1.7x | 8.2x | |
| $779M | n/a | n/a | |
| $774M | 41.1x | -274.9x | |
| $773M | 640884.6x | -7.0x | |
| $768M | n/a | n/a | |
| $761M | 3.7x | -43.0x | |
| $759M | n/a | -7.5x | |
| $757M | 185.4x | -4.5x | |
| $747M | 4.1x | -61.5x | |
| $746M | n/a | n/a | |
| $744M | 1.3x | 6.9x | |
| $722M | 5.6x | 7.9x | |
| $715M | 8.1x | -5.0x | |
| $700M | 1.6x | 15.4x | |
| $698M | 5.4x | -3.7x | |
| $677M | n/a | -2.5x | |
| $666M | 6.4x | 28.6x | |
| $666M | 2.9x | 13.0x | |
| $660M | n/a | n/a | |
| $657M | 7.4x | 37.0x | |
| $644M | 9.3x | -2.8x | |
| $637M | n/a | n/a | |
| $620M | 22.1x | -27.0x | |
| $610M | 3.6x | 15.2x | |
| $591M | 72.6x | -60.7x | |
| $590M | n/a | n/a | |
| $574M | 2.0x | 695.6x | |
| $569M | n/a | -2.3x | |
| $557M | n/a | -3.9x | |
| $530M | 8.2x | -38.9x | |
| $524M | n/a | n/a | |
| $522M | 86.3x | n/a | |
| $510M | n/a | n/a | |
| $484M | 1.5x | 13.0x | |
| $478M | n/a | n/a | |
| $464M | n/a | n/a | |
| $455M | n/a | n/a | |
| $451M | n/a | n/a | |
| $431M | 3.9x | 883.9x | |
| $430M | 362.8x | -7.7x | |
| $430M | 21.6x | 92.3x | |
| $420M | 79.5x | n/a | |
| $419M | n/a | n/a | |
| $406M | 2.6x | n/a | |
| $406M | 14.2x | -10.0x | |
| $400M | 1.3x | 5.9x | |
| $396M | 10.5x | -30.2x | |
| $382M | 2.3x | 10.8x | |
| $376M | 3.1x | n/a | |
| $375M | n/a | n/a | |
| $357M | n/a | n/a | |
| $329M | 37.8x | -10.4x | |
| $327M | 6.3x | -92.2x | |
| $325M | n/a | n/a | |
| $323M | 2.0x | 3.5x | |
| $321M | 1824.2x | -2.9x | |
| $320M | n/a | -3.2x | |
| $318M | 1.3x | 8.0x | |
| $316M | n/a | n/a | |
| $313M | n/a | -2.9x | |
| $302M | n/a | n/a | |
| $298M | 3.1x | -3.1x | |
| $292M | n/a | -2.0x | |
| $289M | n/a | n/a | |
| $289M | n/a | -3.0x | |
| $282M | 4.1x | 14.6x | |
| $281M | 0.8x | 7.0x | |
| $278M | n/a | -1.4x | |
| $274M | 1.6x | -2.7x | |
| $272M | 32.0x | -1.6x | |
| $268M | 1327.3x | n/a | |
| $242M | 4.0x | 8.0x | |
| $234M | n/a | n/a | |
| $233M | 8.0x | n/a | |
| $229M | 3.4x | -0.9x | |
| $227M | n/a | n/a | |
| $225M | n/a | n/a | |
| $220M | n/a | n/a | |
| $209M | 100.0x | -2.5x | |
| $206M | 73.0x | n/a | |
| $203M | 8.8x | -1.8x | |
| $201M | 11.1x | -3.7x | |
| $199M | 36.2x | -4.4x | |
| $196M | 2.1x | 18.5x | |
| $189M | 1.6x | -1.0x | |
| $189M | n/a | -2.4x | |
| $189M | 2.1x | -6.1x | |
| $180M | 1.5x | 15.5x | |
| $176M | 18.0x | -1.6x | |
| $175M | 4.0x | 21.5x | |
| $167M | 56.6x | -4.7x | |
| $166M | n/a | n/a | |
| $162M | 21.3x | -6.8x | |
| $159M | n/a | n/a | |
| $157M | n/a | -1.1x | |
| $154M | 2.6x | n/a | |
| $152M | 228.7x | -1.8x | |
| $149M | n/a | n/a | |
| $145M | n/a | -1.5x | |
| $144M | 600.6x | -10.4x | |
| $141M | n/a | -1.2x | |
| $134M | n/a | -0.7x | |
| $133M | 0.5x | -0.4x | |
| $133M | 171.7x | n/a | |
| $128M | n/a | -8.7x | |
| $125M | 2.7x | -12.4x | |
| $104M | 503.4x | -1.9x | |
| $99.5M | 8.7x | -0.5x | |
| $98.6M | n/a | n/a | |
| $98.5M | n/a | n/a | |
| $96.8M | n/a | n/a | |
| $86.7M | n/a | -1.2x | |
| $86.6M | n/a | -1.0x | |
| $84.9M | n/a | n/a | |
| $83.3M | 26.5x | -2.9x | |
| $62.5M | 2.1x | -0.7x | |
| $60.2M | 18.6x | -6.8x | |
| $59.5M | 9.9x | -3.8x | |
| $57.8M | 6.8x | -1.6x | |
| $56.5M | n/a | n/a | |
| $54.4M | n/a | n/a | |
| $46.5M | 7.9x | -5.1x | |
| $46.1M | 2.2x | -0.7x | |
| $45.0M | 8.7x | -8.1x | |
| $43.4M | 7.3x | -1.8x | |
| $42.2M | n/a | n/a | |
| $39.7M | n/a | -1.8x | |
| $38.9M | 8.2x | n/a | |
| $37.0M | n/a | n/a | |
| $36.8M | n/a | n/a | |
| $32.6M | n/a | n/a | |
| $31.5M | 25.3x | n/a | |
| $19.1M | 4.2x | -0.3x | |
| $14.8M | 1.5x | -1.2x | |
| $14.3M | 0.6x | -0.7x | |
| $1.5M | n/a | n/a | |
| $1.2M | n/a | n/a | |
| -$2.7M | -0.1x | 0.0x | |
| -$11.0M | -7.0x | 0.1x | |
| -$17.6M | -16.2x | 0.4x | |
| -$31.3M | n/a | 0.3x | |
| -$34.8M | -15.0x | 0.4x | |
| -$38.2M | -2.2x | 0.3x | |
| -$38.3M | n/a | n/a | |
| -$43.2M | -0.9x | 0.1x | |
| -$44.6M | -11.4x | 0.8x | |
| -$48.9M | n/a | 0.2x | |
| -$49.8M | -32.3x | 0.3x | |
| -$52.8M | -6.2x | n/a | |
| -$55.1M | -0.3x | 0.8x | |
| -$60.0M | n/a | 0.4x | |
| -$83.2M | -4.4x | 0.4x | |
| -$91.2M | -29.0x | 0.5x | |
| -$94.4M | n/a | n/a | |
| -$134M | -10.0x | 0.3x | |
| -$136M | n/a | 2.8x | |
| -$156M | -182.3x | 0.7x | |
| -$163M | n/a | 2.0x | |
| -$203M | n/a | 1.2x | |
| -$240M | -3.8x | 1.2x | |
| -$263M | -152.0x | 1.4x | |
| -$295M | n/a | 1.0x | |
| -$1.5B | -4.7x | 9.2x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Biopharmaceuticals